Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total value of $205,607.81. Following the completion of the transaction, the insider owned 3,885,115 shares of the company’s stock, valued at approximately $27,700,869.95. This represents a 0.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.41, for a total transaction of $1,426,425.00.
• On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.11, for a total transaction of $273,735.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total transaction of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

Shares of TRDA stock opened at $6.80 on Friday. Entrada Therapeutics, Inc. has a 1-year low of $5.02 and a 1-year high of $16.45. The company has a market cap of $264.79 million, a price-to-earnings ratio of -1.72 and a beta of -0.25. The stock has a 50 day simple moving average of $7.00 and a 200-day simple moving average of $9.04.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Weiss Ratings raised Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Roth Capital restated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Guggenheim cut their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Trading of Entrada Therapeutics

A number of large investors have recently bought and sold shares of TRDA. Baker BROS. Advisors LP increased its position in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares during the period. 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $29,854,949. BlackRock Inc. purchased a new position in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $19,013,000. Wellington Management Group LLP increased its holdings in shares of Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after purchasing an additional 90,339 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.